Literature DB >> 8391305

Characterisation of a vindesine-resistant human small-cell lung cancer cell line.

S Ohta1, K Nishio, S Kubo, M Nishio, T Ohmori, T Takahashi, N Saijo.   

Abstract

We established a vindesine-resistant (x 11.6) human small-cell lung cancer cell line (H69/VDS) by stepwise exposure of parent line H69 to vindesine. H69/VDS showed cross-resistance to taxol (x 10.1), vincristine (x 6.9) and colchicine (x 3.4) but not to doxorubicin, cisplatin or etoposide. There was no significant difference in intracellular [3H]-vincristine and doxorubicin accumulation between H69 and H69/VDS cells. The human mdr1 mRNA was not detected in either of the cell lines. These results indicated that H69/VDS did not express a typical multidrug resistant phenotype. Addition of 20 microM verapamil enhanced the growth inhibitory effect of vindesine on both H69/VDS (x 12.0) and H69 cells (x 3.8). The amount of total tubulin in H69/VDS cells was lower than that in the H69 parental cells. No significant increase was observed in the amount of total and polymerised tubulins of H69 cells. In H69/VDS cells, however, verapamil increased the amount of total tubulin to the level of parental cells, but decreased the amount of polymerised tubulin. Modulation of tubulin may play a role in the resistance to vindesine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8391305      PMCID: PMC1968300          DOI: 10.1038/bjc.1993.289

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin.

Authors:  A M Minotti; S B Barlow; F Cabral
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

2.  Characterization of an etoposide-resistant human small-cell lung cancer cell line.

Authors:  K Minato; F Kanzawa; K Nishio; K Nakagawa; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Quantitation of cellular tubulin in microtubules and tubulin pools by a competitive ELISA.

Authors:  D Thrower; M A Jordan; L Wilson
Journal:  J Immunol Methods       Date:  1991-01-24       Impact factor: 2.303

4.  Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.

Authors:  K Yusa; T Tsuruo
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

Review 6.  The cell biology of multiple drug resistance.

Authors:  W T Beck
Journal:  Biochem Pharmacol       Date:  1987-09-15       Impact factor: 5.858

7.  A phosphoglycoprotein associated with taxol resistance in J774.2 cells.

Authors:  S N Roy; S B Horwitz
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

8.  MDR1 gene expression in lung cancer.

Authors:  S L Lai; L J Goldstein; M M Gottesman; I Pastan; C M Tsai; B E Johnson; J L Mulshine; D C Ihde; K Kayser; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

9.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

Authors:  I B Roninson; J E Chin; K G Choi; P Gros; D E Housman; A Fojo; D W Shen; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

10.  Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane P-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration.

Authors:  P Nygren; R Larsson
Journal:  Biosci Rep       Date:  1990-04       Impact factor: 3.840

View more
  8 in total

1.  In vitro and in vivo modulation by rhizoxin of non-P-glycoprotein-mediated vindesine resistance.

Authors:  H Arioka; K Nishio; Y Heike; S Abe; N Saijo
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.

Authors:  Y Heike; M Takahashi; T Ohira; H Arioka; Y Funayama; K Nishio; H Ogasawara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 3.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

4.  Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.

Authors:  S Dhar; P Nygren; K Csoka; J Botling; K Nilsson; R Larsson
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

5.  High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.

Authors:  Victor S Goldmacher; Charlene A Audette; Yinghua Guan; Eriene-Heidi Sidhom; Jagesh V Shah; Kathleen R Whiteman; Yelena V Kovtun
Journal:  PLoS One       Date:  2015-02-11       Impact factor: 3.240

6.  Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6.

Authors:  Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio
Journal:  Jpn J Cancer Res       Date:  2001-07

7.  Characterisation of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids.

Authors:  V Debal; N Allam; H Morjani; J M Millot; D Braguer; F Breillout; M Manfait
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

8.  Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines.

Authors:  Y Iwamoto; K Nishio; H Fukumoto; K Yoshimatsu; M Yamakido; N Saijo
Journal:  Jpn J Cancer Res       Date:  1998-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.